Title

Biolocity Announces 2026-2027 Awardees Advancing the Future of Cancer Care, Surgery, Diagnostics, and Healthcare Delivery

ID
Jun 25, 2026 | By Kelly Petty
News Image
Audience members sit around a conference table in a bright meeting room, listening to a speaker holding a microphone; laptops, notebooks, and coffee cups are visible on the table near large windows.
Image Caption
Judges from industry, business, medicine, and academia listen to teams describe their projects during Biolocity Pitch Day in May.
Widgets

From safer surgeries and expanded cancer treatment options to precision diagnostics and healthcare workforce resilience, Biolocity’s recently announced 2026-2027 cohort and seed funding group are tackling some of medicine's most complex challenges. 

The commercialization program has selected a new class of innovators from Emory University and Georgia Tech whose technologies have the potential to transform patient care and improve health outcomes. Teams presented their projects to a panel of judges from industry, business, medicine, and academia during Biolocity Pitch Day in May.

“This year's Biolocity cohort reflects the breadth and strength of innovation happening across Emory and Georgia Tech. From improving cancer drug discovery to making surgery safer and addressing healthcare workforce challenges, these teams are tackling complex problems with creativity, rigor, and a commitment to improving lives. We are excited to support them as they transform promising discoveries into real-world impact,” said Angela Gill Nelms, director of Biolocity.

The 2026-2027 program cycle includes a full Biolocity cohort and a seed funding group. Full-cohort teams will participate in Biolocity’s intensive commercialization programming through biweekly, milestone-focused meetings centered on strategic development, execution, and investor readiness.

Seed-funded teams will participate in quarterly commercialization and milestone review meetings designed to support promising technologies at different stages of commercialization as they advance toward impact.

“Biolocity was designed around a simple idea: transformative innovations don't all start from the same place, so they shouldn't all receive the same type of support. By offering both an intensive cohort experience and seed funding opportunities, we can meet teams where they are,” Nelms said. “Early-stage technologies gain momentum, while teams at more advanced stages of commercialization receive the structure, mentorship, and guidance needed to accelerate toward impact."

Through an intensive, multi-stage application and evaluation process, Biolocity identifies high-potential technologies and equips innovators with the strategic guidance, mentorship, and expertise needed to accelerate progress and position innovations for real-world impact. 

Participating teams receive support including pitch coaching, market and competitive assessments, milestone development, and commercialization guidance. Faculty innovators and project teams work closely with experienced entrepreneur advisors to identify risks, strengthen development strategies, and position their technologies for downstream funding and market success.

Tags

Tags

Media Contact

Contact the BME Communications team to connect with a faculty member or student about academics or research happening in the Wallace H. Coulter Department of Biomedical Engineering.